 Arbutus Biopharma Corporation NASDAQ: ABUS and Vaccitech plc NASDAQ: VACC have collaborated to evaluate combination treatment for chronic hepatitis B virus who are already receiving standard-of-care nucleostide reverse transcriptase inhibitor NrtI therapy. The Phase 2a trial will evaluate the safety, pharmacokinetics, immunogenicity, and antiviral activity of Arbutuss AB-729, followed by Vaccitechs VTP-300, in NrtI-suppressed subjects. 